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Generating far over 1 trillion USD of revenue (De-
loitte, 2015), the pharmaceutical industry should only 
have one realistic aim beyond the provision of corpo-
rate profit: treating diseases. This aim can be reached 
by efficient drugs with appropriate side effect profile, 
namely safe active ingredients. By drug efficacy we 
mean its ability to promote a quantifiable biological 
response. In case of drug safety, the question is: what 
secondary (and usually negative) effect does the drug 
have on the human body? The clinical evidence (also 
referred to as scientific evidence) is determined by the 
drug’s efficacy and safety profile. As a marketing-ori-
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This study aims to investigate how much the market performance of drug therapies is influenced by their 
scientific evidence and price level. Compared to the seemingly simple objective, performing the analysis in 
the pharmaceutical industry makes the evaluation very complex. Examining the purchase decision process 
in the prescription drug market, besides the patient as the final consumer, the prescribing physician has 
the largest decision potential. In addition, the authors cannot ignore the healthcare system financing the 
therapy either, not to mention the interlacements of regulations, manufacturer interests, their marketing 
potential and marketing activities. This complexity makes it impossible to describe the pharmaceutical 
industry in uniform terms. The literature search also confirms that the mentioned complexity makes it 
hard to draw unambiguous conclusions. In spite of that –with a positivistic approach- the authors live with 
the assumption that scientific evidence (better efficacy and safety profile) should be awarded on the market 
on the aggregate level. It is inevitable to clarify at the very beginning that the authors investigate active 
pharmaceutical ingredients (APIs) and not brands in the recent study. With all this in mind, their intention 
is to introduce a novel approach for the evaluation of the relationship between the product characteristics 
(clinical evidence of APIs) and their market performance. In order to examine the relationship the authors 
involved APIs that belong to the same indication group, having the same mechanism of action and which 
have been in the generic competition for years after their patent have expired. As a model they perform 
the analysis with antihypertensive drug therapies. The authors consider that it is possible to rank the active 
ingredients of drug therapies on the basis of their efficacy and safety, based on relevant clinical literature. 
The result of ranking serves as the starting point of the analysis. Unequivocally, the authors do not forget 
about the additional factors that significantly influence the market performance of APIs, but delibera-
tely do not involve these factors in the recent analysis. These factors are the different reimbursement and 
funding policies, marketing activity of the manufacturers, country-of-origin effect, the impact of clinical 
guidelines and clinical literature, and their effect on each other. There is one exception, since the article 
partially deals with the influence of price level on the market performance. In contrast with the majority of 
the available literature, this study aims to explore the identifiable patterns by investigating the European 
pharmaceutical market on system-level.
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ented analysis we would like to investigate the effect of 
scientific evidence on market performance. The fun-
damental assumption of our research is that the vari-
ous drug therapies can be ranked based on these two 
factors. In order to define the ranks, we use the basic 
principles of evidence based medicine in the analysis 
(Sacket, 1997; Friedland, 1998; Botz – Szűcs, 2014; 
Hamer –  Collinson, 2014). Evidence based medicine is 
the explicit and judicious use of current best evidence 
in making decisions about the care of patients based 
on  the best available external clinical evidence from 
systematic research. Following the principles, the re-
cent article assumes that clinical ranks can be defined 
for APIs that have instead of have the same method 
of action, by the evaluation of the relevant clinical lit-
erature on efficacy and safety. We must also mention 
that there are authors who question the general accept-
ability of evidence based medicine (Greenhalgh et al., 
2014; Spence, 2014). This skeptical approach, however, 
is not attributable to the unacceptability of the prin-
ciples, but rather to the hardly processable amount of 
literature serving as the basis of analysis and the strong 
influence of the pharmaceutical industry on the stud-
ies. Concerning the influence of the industry, Sismon-
do suggests that as many as 40% of published articles 
focusing on specific drugs are ghost managed, i.e. di-
rectly influenced by pharmaceutical manufacturers. 
Even independent of detailers, responsible physicians 
and medical researchers search the literature to gather 
evidence about the best treatments. Published scientific 
articles are the sources of medical information with the 
highest authority. Systematic reviews and meta-anal-
yses almost all start with the published literature, 
so even fully independent reviews are influenced by 
ghostly activities (Sismondo, 2007).
The effect of the efficacy and safety  
on the prescription of drug therapies
In their paper, Borjádi and Juhász emphasize that 
‘Drugs are not the objects of desire like most consum-
er goods but they are real consumer needs” (Borjádi 
– Juhász, 2003).  As mentioned previously, our arti-
cle evaluates this question from the marketing point 
of view. Likewise, the authors summarize the corre-
sponding marketing literature and build their analysis 
on the marketing principles. With respect to this, let’s 
examine how this statement can be interpreted in the 
drug prescription process. The only aim of the patient 
taking the drug is to get treated by the most efficient 
therapy with the least possible side effects. Pursuant to 
the vocation, the prescribing physician’s primary inter-
est cannot be different from that of the patient. The pay-
er’s responsibility is more complex in this issue even 
theoretically, since on an economic basis the payer has 
to choose the recommended therapy within the given 
indication based on the cost-benefit ratio (Bootman – 
Townsend, 1991).  When concerning the benefit of the 
therapy, efficacy and safety may be a dominant factor, 
and during the comparison of therapies the payer also 
has to consider which therapy is scientifically proven 
to be the best. Of course, the question is far from be-
ing this simple. On one hand, the evaluation of the sci-
entific evidence (and accordingly the ranking that the 
authors introduce) is not a simple task. The complete 
information of the stakeholders is not present in the 
system. This is attributable among others to the biasing 
effect of actors with different levels of awareness and 
corporate and political interests as well as the complex 
nature of evaluation. On the other hand, the choice and 
therefore market performance of drugs (in volume) is 
not solely determined by their scientific evidence. The 
cost of the therapy and the availability of products are 
central questions and of course, product promotion 
also has a significant influencing effect. First of all, we 
summarize the effect of clinical evidence in the light of 
corporate marketing activities.
Generally investigating marketing investments, 
Berndt et al. had several observations concerning the 
market of anti-ulcer drugs. Marketing investments un-
equivocally have a positive influence on drug sales, 
which obviously effect spreads from the innovator 
product to the follower generic products. The authors 
mention that switching between therapies is fast-
er when the manufacturer can prove an actual added 
value (e.g. lower dose, less side effects) (Berndt et al., 
1996).
Through contact with pharmaceutical representa-
tives and attendance on symposiums, physicians be-
come well-informed on the drugs’ clinical evidence 
(Gönül et al., 2001), and these activities have signifi-
cant informative and persuasive effect (Narayanan et 
al., 2005). Clinically, the most important information 
of all is the efficacy and safety of drugs. In the litera-
ture, Azoulay is the first to deal with the relationship 
between the scientific value of a drug and sales data 
(Azoulay, 2002). Investigating the market of H2 antag-
onists, he concludes that marketing (promotion) has a 
much more dominant effect on the demand of drugs 
than their clinical evidence. Still, we shall also consid-
er the effect of the latter as significant both statistically 
and economically. Thoroughly studying the paper, one 
may also recognize that in his research, the author has 
not examined how much the effect of promotion is af-
fected by clinical evidence (the effect of the physician 
being visited with a clinically more beneficial drug). 
However, clinical evidence may also present indirect-
ly in drug prescribing. As a conclusion of his study, 
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Azoulay states that on the market of H2 antagonists, 
Zantac was able to overshadow Tagamet, which was 
ahead of it, due to its more appropriate clinical profile.
Further positive examples of a clinically more ad-
vantageous compound being able to take over the mar-
ket:
•  The world’s largest blockbuster, the manufacturer 
of Lipitor (Warner-Lambert) has widely commu-
nicated that its compound is as efficient in lower-
ing cholesterol levels as its competitors (Merck: 
Zocor, Bristol Myers-Squibb: Pravachol) but this 
effect is reached by a much lower dose (Winslow, 
2000). 
•  In relation to our later research results, the sto-
ry of Vasotec (enalapril) and Capten (captopril) is 
also an interesting example on the market of ACE 
inhibitors. Enalapril has appeared on the market 
after captopril and was still able to reach a much 
higher share on the US market. The main reason 
of this was Merck’s appropriate marketing activity 
(Werth, 2013). 
The example of Zoloft and Prozac may be of inter-
est too. However the two compounds can be considered 
very similar clinically, Zoloft was able to overshadow 
Prozac from the second position. By not being able to 
come up with real advantages in the reasoning, Zoloft 
is an example for the persuasive power of marketing 
(Cutler – Berndt, 2007).
If we investigate the marketing effect of visits by 
pharmaceutical sales representatives, we will not get 
an unequivocal answer based on the literature. While 
there are authors who think there is a positive relation-
ship between visits by pharmaceutical sales representa-
tives and prescribing (Gönül et al., 2001), others think 
that the relationship is weak (Mizik – Jacobsen, 2004), 
and we also found literature, where the authors state 
that there is no relationship whatsoever between the 
two (Rosenthal et al., 2003). Leeflang et al. think that 
the conflicting results are due to the inaccuracy of re-
search. In their study, they claim that researches do not 
treat brand portfolio marketing investments uniformly, 
therefore these can bias the results, and the physician’s 
responsiveness may also vary during the promotion of 
the different therapies (Leeflang –  Wieringa., 2010). 
Based on studies using aggregated data for the anal-
ysis, we can conclude that the marketing activity of 
manufacturers (e.g. visits by pharmaceutical sales rep-
resentatives, symposiums) have an unequivocally posi-
tive effect on drug sales (Chintagunta – Desiraju, 2005; 
Narayanan et al., 2004; Narayanan et al., 2005; Neslin, 
2001; Rizzo, 1999). In a meta-analysis (Kenneth et al., 
2016) will be found that there are several factors which 
directly and indirectly affect the physician’s prescrip-
tion pattern. They find that the curing effect is the most 
important factor, but the influence of patients and ad-
vertising can be significant factors as well. The above 
examples show that the statement – although verified 
on aggregated level – is not necessarily applicable for 
all therapeutic groups and in each case. That is why it 
is essential to examine this issue in details. 
Based on the foregoing, Venkataraman and 
Stremersch studied the relationship of clinical evi-
dence and the number of prescriptions (sales, indirect-
ly), just like Azaulay (Venkataraman –  Stremersch, 
2007). Interestingly, they consider their work as a first 
in the investigated issue – just like Azaulay. The study 
investigates how much a drug’s clinical advantage (in 
terms of safety and efficacy) influences the effect of 
pharmaceutical actors’ marketing activities (visits and 
professional symposiums and B2C activities appearing 
in patient requests) on prescription. In their economet-
ric model, the authors examined the following factors:
•  detailed biannual visiting activity of a US phar-
maceutical company by months for 3 drug groups 
(statins, gastrointestinal agents, erectile dysfunc-
tion),
•  the attendance of symposiums organized by the 
manufacturer for doctors,
•  drug requests by patients at the 2774 studied phy-
sicians,
•  the number of prescriptions and the amount of dis-
tributed drugs, 
•  efficacy (meta-analysis of clinical trials, ‘Z-values’ 
compared to placebo),
•  side effect profile (FDA, drug approval database).
According to their theory, more efficient therapies 
decrease the uncertainty of physicians, therefore con-
vincing physicians becomes easier via various market-
ing activities (as Azoulay has described it in his paper 
in 2002). In terms of safety, drugs with less favorable 
side effect profile increase the physician’s uncertainty. 
This uncertainty can be decreased by marketing activ-
ities but because of the earlier described, physicians 
prefer safer therapies. Of their conclusions it is worthy 
to emphasize that it is important to examine the differ-
ent drug groups and drug brands separately as it is hard 
to make a valid conclusion in general. Nevertheless, 
the authors claim that prescription of drugs is higher 
where a more efficient or safer therapy is considered. 
Also, physicians take their patients’ requirements more 
into consideration in such cases. It is necessary to em-
phasize that the authors based their results on US data. 
According to Scherer’s study, switching between 
different drugs is made more difficult by the established 
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prescription habits and the possible negative conse-
quences that the doctors will face (e.g. negative profes-
sional and perhaps legal consequences of prescribing 
a new drug). However, this effect may be decreased if 
genuinely relevant and objective information is avail-
able on a competing product. In such cases, switching 
takes place faster (Scherer, 1990). 
The role of price in decision making on drug 
prescription
The role of price in the decision making process may 
vary in the different countries; therefore literature is 
also not unified in the question whether marketing 
costs decrease price sensitivity. Ceteris Paribus, doc-
tors should choose the cheapest therapy, which can 
be strongly modified by the convincing function of 
marketing, predominantly because the ceteris paribus 
principle is really difficult to evaluate among drug 
therapies (De Laat et al., 2002; Leffler, 1981; Hurwitz 
– Caves, 1988). If doctors become less price sensitive 
as a result of corporate marketing activity, this process 
is considered by De Laat et al. as ‘increase of brand 
loyalty based on factors other than brand characteris-
tics’ (De Laat et al., 2002, p. 80.). This leads to higher 
prices, which finally emerges as a loss of the society 
(Windmeijer et al., 2005). In contrast with Windmei-
jer et al., Leeflang and Wieringa state that this effect 
is not significant (Leeflang – Wieringa, 2010). About 
their work, it is important to mention that it has inves-
tigated the quasi totally funded Dutch pharmaceutical 
market. In a Swedish study (Semark et al., 2013) the 
registered data of dispensed drugs were analyzed to-
gether with the sociodemographic data of the patients. 
For each of the diagnostic groups (chronic obstructive 
pulmonary disease, depression, diabetes, and osteo-
porosis), selected drugs were dichotomized into cost 
categories, lower and higher price levels. They found 
that individual factors such as gender, age, education, 
income, foreign background, and type of caregiver 
(public or private) influenced the prescribing of drugs 
of different price levels, although in some cases, the 
influence was relatively small. Because the average 
price of the cheaper drugs in each diagnostic group 
was between 19% and 69% versus more costly drugs, 
there is a risk that factors other than medical needs 
are influencing the choice of drug. However, medical 
reasons for the observed differences cannot be ruled 
out.
Based on the results of Cleanthous et al., the exis-
tence of health insurances and the increase of the ex-
tent of reimbursement, decrease price sensitivity and 
price regulation in turn increases price sensitivity on 
the pharmaceutical market. This statement explains 
why authors investigating different countries get total-
ly different results (Cleanthous et al., 2005). For this 
reason it is crucial to compare the drug policy tools of 
the analyzed countries.
Table 1
Supply and demand side drug policies in 9 European countries in 2017
UK DE NL FR IT ES HU RO PL
D
em
an
d 
sid
e
Promotion of generic prescribing x x x x x
Mandatory generic prescribing x x x
Generic substitution x x x x x x
Mandatory INN prescribing x x x x x x
Officially defined retail and 
wholesale margins x
x (ex-
tremely 
high)
x x x x x x
Authorized discounts and volume 
agreements x x x x x x x x
Clinical guidelines x x x x x x x x x
Reimbursement system x x x x x x x x x
Su
pp
ly
 si
de
External reference prices x x x x x x x x
Internal reference prices x x x x x x x x
VAT pharmaceuticals (standard) 
(%) 0 (20) 19 (19) 6 (21)
2/10 
(20) 10 (22) 4 (21) 5 (27) 9 (20) 8 (23)
Generic price depends on the 
price of the innovator - - - 50%
min 
20% -
20-
50% -
20-
50%
(Author’s edit, Source: Barbu, 2012; Dylst et al., 2012; Kaplan et al., 2012; Kanavos et al; 2011a,2011b;
Panteli et al., 2016;Thomson-Mossialos 2010; Vogler, 2012; Vogler et al., 2015) 
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The effect of drug policy tools on different 
pharmaceutical markets
The role of authorities on the pharmaceutical market 
varies in the different countries of the world. Consid-
ering the healthcare financing systems three major 
health care models are used in industrialized nations, 
including: the Beveridge model, the Bismarck mod-
el, and health care systems based on private found-
ing. Concerning the European healthcare systems, the 
foundations of the Beveridge and Bismarck models are 
the dominant. The Beveridge model provides health 
care for all citizens and is financed by the government 
through tax payments (UK, Italy, Spain). The Bis-
marck model uses an insurance system and is usually 
financed jointly by employers and employees through 
payroll deduction. Unlike with the US insurance indus-
try, Bismarck-type health insurance plans do not make 
a profit and must include all citizens. Doctors and hos-
pitals tend to be private in Bismarck countries (Germa-
ny, France, Netherland, Hungary, Poland) (Busse et al., 
2007; Chintagunta – Desiraju, 2005; Wallace, 2013). 
The characteristics of the  funding system and the 
country’s drug policy largely determines what interest 
physicians, industrial actors and patients need to take 
into consideration in the process of drug purchase. For 
the analysis, it is necessary to review and compare the 
generic funding and reimbursement tools of the coun-
tries involved in our research. The analysis is helped 
by the Table 1, which summarizes the demand and sup-
ply side pharmaceutical market regulations of the nine 
countries involved in the analysis. Table 1 is a result of 
proprietary research activity.
We will return to the role of governmental funding 
and reimbursement policy during the analysis, howev-
er only on a superficial level, since the impact of the 
reimbursement and funding system could be the scope 
of an independent research.  In this chapter we only 
bring up a few examples to illustrate trends, emerging 
from the difference of drug policies in purchasing de-
cision. Investigating the Dutch pharmaceutical market, 
Leeflang and Wieringa concluded that in case of most 
drugs, the price of the drug has no effect on demand 
and doctors’ decisions. Their results were supported by 
the study of Gönül et al. in 2010 (Leeflang – Wierin-
ga, 2010). Consequently the authors declare that only 
clinical considerations should be present during drug 
prescription, both by doctors and patients. This could 
be strongly arguable as a general statement. However 
the statement is less debatable, if the almost perfectly 
insured Dutch pharmaceutical market is considered. 
Dutch doctors and patients care less about the financial 
considerations when choosing a medicine.
Governmental policies play a great role in the for-
mation of price level as well. The tools for this aim may 
be the mandatory price reduction for generics against 
innovator products (e.g. in France, the first generic has 
to set a price at least 50% lower than the originator), tax 
rates, as well as external and internal reference prices.
In relation to the role of drug policy, we should 
not ignore to mention the high influence of clinical 
guidelines on doctors’ decision. These professional 
guidelines represent the interest of both authorities 
and professional stakeholders. Their primary aim is 
to influence the prescribing decision (Spurling et al., 
2010). However, in terms of the clinical guidelines, 
it is always indispensable to examine the interests in 
the background as well (e.g. besides professional inter-
ests, reimbursement protocols; reduction of drug costs, 
pharmaceutical lobby, etc., may also be present). 
In our analysis, we investigate generic pharmaceu-
tical markets where the patents of active ingredients 
have expired for at least 5 years. This is necessary be-
cause we strongly believe that clinical superiority can 
only predominate the market in a competitive land-
scape, after a proper amount of time. It is inevitable to 
mention that clinical evidence helps to launch the in-
novator product and has a drag on effect in genericized 
markets. The aforementioned clinical guidelines also 
promote this process. When examining governmental 
factors, it is therefore necessary to examine how these 
factors influence (stimulate) the purchase of generic 
drugs. The Figure 1 shows the share of generic drugs 
in certain countries in terms of volume and sales rev-
enue. It is interesting to compare the regulatory drives 
(Support of generic prescription, Mandatory generic 
prescribing, Generic substitution, Mandatory INN pre-
scribing) leading to high values in the countries with 
the most significant generic share (DE, PL, NL, UK).
 
 
 
Figure 1
Generic market share in European countries 
(Source: Generics Initiative, 2014
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Research Questions and Framework
Our assumption is that clinical evidence of drugs has 
a positive effect on their market performance. As we 
could see, literature is ambiguous in this question. This 
is due to that in most cases the authors examined a sin-
gle country only and because there are many mutually 
interrelated variables. The purpose of our research is to 
analyze the relationship with a rather novel approach, 
through the example of several countries. Of course, 
it is fundamental to define the framework in which 
the statement is considered to be valid. For the sake 
of comparability, we define the depth of our study at 
the level of active ingredients. We do so because on a 
scientific basis this is the level where it is meaningful 
to make a distinction between drug therapies. (We can 
live with this assumption, because due to the gener-
ic concept, the rigidity of the drug approval process 
provides identical quality for products containing the 
same active ingredients.) Consequently the volume of 
aggregated sales associated to active ingredients may 
provide good comparability of the different drug thera-
pies. Another important criterion is that our study was 
performed in the market of generic drugs. The monop-
olistic market of patented active ingredients deserves 
distinct evaluation. In the research we involved active 
ingredients if their patent expired at least 5 years ago. 
The post-patent period is critical, since generic market 
entries redefine the market. A 5-year timeframe may 
be sufficient for the development of a new balance as a 
result of regulation and free competition.  For the afore-
mentioned reason it is also a stipulation that innovative 
drug therapies should not appear in the examined indi-
cation in the examined period which could redefine the 
market. Our research was conducted in the market of 
prescription drugs. In the market of prescription drugs, 
physicians act as the agents of patients, so the consum-
er is well distinguishable from the decision maker in 
the purchasing process. Assuming a clinically respon-
sible drug prescription, the doctor’s primary motiva-
tion must be the selection of a clinically appropriate 
therapy. Therefore due to the unavoidable control of 
doctors in the market of prescription drugs, the clinical 
evidence (meta-analyses and guidelines) has a larger 
effect than in the market of OTC drugs. Another argu-
ment in favor of examining the market of prescription 
drugs is that due to the rigor associated with pharma-
ceutical advertising, the effect of advertisements tar-
geting the final consumer is negligible (Gönül et al., 
2001). According to our assumption, the clinical ev-
idence presents in the market sales of active ingredi-
ents within the described framework in the following 
way: Following the expiry of patent protection, generic 
manufacturers prefer therapies with active pharmaceu-
tical ingredients, which are the most appropriate for 
convincing the prescribing physician. In the medical 
persuasion, the clinical evidence of active pharmaceu-
tical ingredients has a critical role, and this effect is 
further supported by the above mentioned professional 
guidelines. In order to avoid competitive disadvantage, 
generic manufacturers develop and market the clinical-
ly most appropriate therapy, and allocate the market-
ing investments to this territory, thereby increasing the 
level of knowledge in the market. Since our study was 
performed on the level of active pharmaceutical ingre-
dients – and not on the level of manufacturer brands – 
it has to prevail in the generic competition that the clin-
ically more beneficial active pharmaceutical ingredient 
can reach higher sales volumes. We have to emphasize, 
that the previous statement stands in theory, but this 
relationship is seriously affected by further factors. In 
spite of that we deliberately avoid the evaluation of the 
impact of further factors, except one: the effect of the 
price level.   
In our analysis we could not ignore the effect of the 
price level of the discussed drug therapies. The coun-
tries involved in our study typically possess extend-
ed health insurance system and high (100% in several 
cases) reimbursement rates on the basic drugs which 
decreases price sensitivity among doctors and patients. 
On one hand, this effect may vary in the different coun-
tries (e.g. because of low income patient groups), and 
on the other, we should not forget that the payer’s aim 
is to promote choice between the available therapies 
based on optimal cost-benefit rate. When performing 
the study on the level of active pharmaceutical ingre-
dients, it is worth to analyze the influencing force of 
price level characteristic of the individual active phar-
maceutical ingredients. The primary focus of this study 
is therefore to investigate the effect of clinical evidence 
and price level on the market performance of drugs. In 
addition, we will take an outlook on the further factors 
influencing the relation in question.
Drug therapies in the scope of research
We had to choose an indication group for the analysis 
that meets the requirements of the described frame-
work. Our choice was the drug therapies of hyperten-
sion:
•  several drug families are distinguished for the 
treatment of hypertension based on their mecha-
nisms of action (diuretics, ACE inhibitors, ARBs, 
etc.),
•  due to the importance and duration of this field, 
several therapies are known within the drug 
families (e.g. more than 10 ACE inhibitors and 7 
ARBs), 
StudieS and articleS
VEZETÉSTUDOMÁNY / BUDAPEST MANAGEMENT REVIEW
55XLVIII. ÉVF. 2017. 5. SZÁM/ ISSN 0133-0179  DOI: 10.14267/VEZTUD.2017.05.05
•  within these two groups, the expiry of the patent 
protection of active pharmaceutical ingredients is 
well beyond the predetermined limit, 
•  the active pharmaceutical ingredients has pre-
scription status and are available in the analyzed 
countries. 
According to the original concept, we intended to 
rank the anti-hypertensive therapies both by mecha-
nism of action groups and on the level of individual 
active pharmaceutical ingredients (within the groups) 
as well. However, as a result of consultation with doc-
tors, only two groups and their active pharmaceutical 
ingredients were involved in the analysis. These two 
groups are angiotensin-converting enzyme inhibitors 
(ACE inhibitors, ATC code: C9A)) and angiotensin II 
receptor blockers (ARB, ATC code: C9C)). The reason 
of such filtering is that therapies with different mecha-
nism of action are used for the treatment of not only hy-
pertension but other indications too. Since these appear 
in the aggregated sales data, the criteria of comparabil-
ity would not have been met. The chosen two groups 
meet all the criteria as they are prescribed in the same 
range of indication in the vast majority of cases. There 
was no need for any similar exclusion on the level of 
active pharmaceutical ingredients. ACE inhibitors and 
ARB therapies are also prescribed in fixed dose combi-
nations. After discussions with physicians we decided 
to perform the analysis with the mono therapies and to 
exclude the combinations. 
Clinical ranking based on evidence based medicine 
principles
In order to compare active pharmaceutical ingredients, 
it was important to first determine their clinical order. 
Towards, clinical meta-analyses, scientific compara-
tive studies, and professional guidelines were collect-
ed within this indication. The key to the comparison 
of therapies were obviously the results of random-
ized clinical studies and their higher level, systemat-
ic analyses, such as meta-analyses. The formation of 
the scores was a three phase procedure. First of all, 
the authors collected clinical literature, and based on 
that we defined our ‘internal’ ranking of the APIs. The 
clinical literature was classified according to the inter-
nationally accepted classification system of evidence 
based medicine (Botz, 2014) and the order of clinical 
evidence and the ranks was calculated by using the 
weights based on the classification system. (The list of 
clinical literature used for the research is attached in 
Annex 1.) Since the authors are not medical doctors, 
we validated our results with medical doctors (1 inter-
nist, 1 surgeon, and one GP). First, we asked them to 
perform a literature search and rank the APIs based on 
their literature search (evidence based medicine scor-
ing was introduced to them). As a second round we 
asked them to confirm/ refine the scoring with their 
professional experience. We got the final ranking af-
ter discussing the results jointly. We did not initiate to 
gather and analyze data until the closure of the valida-
tion process, in order to ensure the independency of 
our judgment. The clinical evidence of therapies on the 
API level was considered universal for the concerned 
countries. 
From medical point of view, the use of ARBs is rec-
ommended against ACE inhibitors due to their more fa-
vorable side effect profile. The clinical ranking of ACE 
inhibitor drug therapies is indicated on the Figure 2.
As a limitation, of course this ranking could be re-
fined in the future (more reviewers, more literature, 
and more robust methodology). However the authors 
rather consider this research a medical-oriented, and 
not a marketing-oriented goal. All in all, the authors 
think, the research and work and the involvement of 
medical doctors justifies the implication of the ranking 
in the recent study.
Market data and Methodology 
We perform and present two types of analyses in the 
recent study. First, we compare the two pharmacologi-
cal groups (ARB vs ACE), and then the active pharma-
ceutical ingredients of ACE inhibitors were compared 
based on sales volume (thousand tablets, moving an-
nual total (MAT)) and sales revenue (EUR, ex factory 
price, moving annual total (MAT)). Information con-
cerning market performance was gained from the IMS 
database made available by Gedeon Richter Plc. On the 
first level of query, the distribution by dosage form was 
examined. Since 99.9% of ACE inhibitors and almost 
100% of ARBs are taken orally worldwide, only oral 
pharmaceutical forms were filtered during the later 
queries. Therapeutic group–country, active pharma-
ceutical ingredient–country, and active pharmaceuti-
cal ingredient–country–brand level queries were also 
performed for the affected markets. In order to secure 
comparability, we analyzed sales volume data in the 
 
 
 
Figure 2
Summary of the relations of clinical evidence
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concerned countries, more punctually we compared 
the sales ratio that describe each API’s market perfor-
mance in the concerned countries. We also took into 
account that the APIs differ concerning defined daily 
dose (DDD) and that different strengths are available. 
The Days of Treatment (DOT) can be given only if we 
know all the mentioned information about the APIs. 
From IMS database we got the sales volume (thou-
sand tablets) in the following breakdown: API-streng-
ht-country. From that data we were able to calculate 
if the ratio of Sales volume (please find later as CU/
MAT) is linearly proportional to DOT. We can confirm 
that the values used for the analysis represent the ratio 
of DOT of the API therapies.
In order to explore interrelations, the markets were 
described by different indices. In addition, the method 
of multidimensional scaling was used for the demon-
stration of similarities and differences between coun-
tries. Multidimensional scaling is a method allowing 
the comparison of objects based on the level of similar-
ity while taking multiple variables into consideration 
at the same time (Malhotra, 2010). The method is capa-
ble to explore data structure in such a way that the ob-
jects are represented as geometric relationships among 
points in a multidimensional space. The advantage of 
the method is the graphic display visualizing the mag-
nitude of differences between the objects and showing 
which objects are close to each other. The statistical 
reliability and validity of the solution is measured by 
R2 value and the stress indicator. The method does not 
provide a direct solution for interpreting the dimen-
sions of the space of perception and object character-
istics. The interpretation may be promoted by several 
ways: based on professional expertise or using different 
evaluation methods with qualitative nature and supple-
mentary calculations such as regression analysis may 
insert characteristics vectors into the perceptual map. 
Thus, as a result of multidimensional scaling, it may be 
determined which objects are close to each other and 
which are more far away and it also gives an idea on 
which dimensions of characteristics form the basis of 
the objects’ spatial localization (Backhaus et al., 2015). 
In our analysis, the countries were placed as objects 
in the multidimensional space, and the similarity data 
were derived from their characteristics.
Results
In accordance with the methodology section, we ex-
amined the ranking of clinical evidence and price level 
of anti-hypertensive drugs and their effect on market 
performance in nine European countries (United King-
dom, Germany, Netherlands, France, Italy, Spain, Hun-
gary, Romania, Poland) (Table 2). When we examined 
the clinical evidence of drug therapies, with the help of 
the medical doctors we concluded that ARB therapies 
are considered to be superior against ACE inhibitors. 
In order to analyze the relationship, therapeutic group–
country level data were queried from the IMS data-
base. Our raw data were as follows: Group-level aggre-
Table 2
Comparative table of ACE and ARB therapies
Country
ARB 
price 
level 
(EUR/ 
CU)
ACE pri-
ce level 
(EUR/ 
CU)
ARB CU 
(ARB/ 
Gros) %
ARB 
EUR 
(ARB/
GROSS) 
% 
ACE CU 
(ACE/
GROSS) 
%
ACE 
EUR(A-
CE/
GROSS) 
%
Price 
level 
differen-
ce index 
ARB:A-
CE
Volume 
differen-
ce index 
ARB:
ACE
Sales 
Revenue 
differen-
ce index 
ARB:
ACE
ARB 
pref. 
index
ES 0,322 0.064 41.91 78.41 58.09 21.59 5.03 0.72 3.63 2.62
DE 0.158 0.025 32.58 75.56 67.42 24.44 6.4 0.48 3.09 1.49
FR 0.196 0.14t7 49.59 56.81 50.41 43.19 1.34 0.98 1.32 1.29
IT 0.249 0.14 43.2 57.53 56.8 42.47 1.78 0.76 1.35 1.03
NL 0.067 0.036 38.87 54.12 61.13 45.88 1.85 0.64 1.18 0.75
UK 0.138 0.054 29.05 51.26 70.95 48.74 2.57 0.41 1.05 0.43
HU 0.113 0.067 29.22 41.12 70.78 58.88 1.69 0.41 0.7 0.29
RO 0.143 0.076 25.73 39.4 74.27 60.6 1.88 0.35 0.65 0.23
PL 0.133 0.085 24.22 33.23 75.78 66.77 1.56 0.32 0.5 0.16
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gated sales volume (thousand tablets) and sales revenue 
(€, ex factory price) of ACE inhibitors and ARBs as 
the sum of hospital and pharmacy sales. (Aggregated 
sales volume allows appropriate comparison of defined 
daily dose of the individual therapies between the two 
groups. This was tested separately.) Derived indicators 
for the characterization of markets:
•  Price level of ARBs and ACE inhibitors: Ratio of 
the revenue and sales volume. Price level charac-
teristic to the individual countries by therapeutic 
groups.
•  Price level difference index: The ratio of the mean 
price level of ARB and ACE inhibitor therapies 
show the extent to which ARB therapies are more 
expensive compared to ACE inhibitors in the giv-
en country.
•  Volume difference index: The ratio of ARB sales 
volume and ACE inhibitor sales volume. Its value 
shows the proportion of ARB and ACE inhibitor 
sales characteristic to the given country.
•  Sales revenue index: The quotient of sales reve-
nues. The value determines the proportion of fi-
nancial outflow (both by consumers and payers) 
for ARB and ACE therapies. It may be also in-
terpreted as a product of volume and price level 
difference index.
•  ARB preference index: Sales revenue index (where 
volume and price both play a role) multiplied by 
the volume difference index. The significance of 
the prescribed volume is square-weighted, and the 
influence of higher ARB prices is also taken into 
account.
Recommendation: In order to support the interpre-
tation of the results, multidimensional scaling has been 
performed (after the percentages were decimalized) (Fig-
ure 3). With this method, it can be appropriately exam-
ined how similar these nine European countries may be 
considered in terms of the market data of ACE and ARB 
therapies. The two-dimensional scatter plots that present 
the similarity of the countries was achieved by running 
the ALSCAL routine of SPSS 22.0 software package with 
standardized variables, using Euclidean distance plot and 
ordinal scale. The value of the stress indicator testing the 
statistical fit was 0.00198 (Kruskal’s stress formula), and 
R2 was 0.999 indicating extremely close fit. 
It is well visible that the countries localized on the 
stretched plain can be excellently evaluated by a 2×2 
matrix. The first dimension is determined by the differ-
ence in the price levels of ARBs and ACE inhibitors, 
while the second dimension is determined mostly by 
the market share of ARBs. Of these countries, only the 
United Kingdom is difficult to be classified into any of 
the 4 groups. The reason is that the UK is characterized 
by relatively low ARB share (its value is almost identical 
with the Hungarian data), despite a higher price level. 
However, this higher price level is far below the German 
and Spanish values where there is indeed a large dif-
ference between the price levels of the two therapeutic 
groups. As described, the point symbolizing the Unit-
ed Kingdom is located very close to the pole symbol-
izing the countries’ center of gravity. When examining 
the value of ARB preference index, a similar pattern 
emerges. The Spanish market ranked first with a high 
sales volume even beside an outstandingly high price 
level of ARBs. The trio of Germany, France, and Italy 
form a group with the value between 1 and 1.5 point. 
In the French and Italian market, high sales volume is 
also supported by lower price level. The German mar-
ket, although lags behind the previous countries in terms 
of volume, however this sales volume is reached beside 
an outstanding price level. In spite of high price level, 
its sales volume exceeds that of the low share countries 
forming the next group. The Dutch market is considered 
to be average in every aspect, while the already men-
tioned UK market (despite its higher price level) is close 
to the last group in terms of ARB sales volume. The last 
group consists of the Hungarian, Romanian, and Polish 
market. These countries are characterized by low share 
of ARB which is accompanied by a price level almost 
comparable with that of the ACE inhibitors. 
Of the two treatment groups, ACE inhibitor thera-
pies were analyzed on the level of active pharmaceuti-
cal ingredients too. In the following table, the first data 
to appear beside the name of the active pharmaceutical 
ingredient is the clinical rank determined by the anal-
ysis. It is followed by the sales volume data by active 
pharmaceutical ingredients characterizing the exam-
 
 
Figure 3
Results of the multidimensional scaling 
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ined markets. The results of the active pharmaceutical 
ingredient–country level query of the IMS database 
were transformed into market share for the sake of 
comparability. The rows of active pharmaceutical in-
gredients with a market share over 10% are marked by 
bold fonts, and the share of the most commonly applied 
active pharmaceutical ingredients was marked by un-
derlining. Table 3 indicates the innovator of the given 
active pharmaceutical ingredients, or if the innovator 
(or the compound) was acquired then the name of the 
holder pharmaceutical company and its nationality.
Based on the results, amongst the ACE inhibitor 
therapies the sales of four compounds can be considered 
significant. Ramipril, enalapril, lisinopril, and perin-
dopril are responsible for 76.6 to 98.8% of the sales in 
volume in the investigated countries. In general, it can 
be stated that these active pharmaceutical ingredients 
have high clinical ranks (1st or 2nd) within the group of 
ACE inhibitors however apparently the proportions are 
shifted in the different countries. From the aspect of 
patients it is considered a positive result that ramipril, 
which takes the first place in clinical ranking, also takes 
the first place based on its share expressed as volume 
in five of the nine countries (UK, DE, FR, IT, PL). In 
addition, it has significant sales share (33%) in Hunga-
ry as well. Its share is more moderate in Spain (17.6%) 
and Romania (18.5%), while it is lagging far behind in 
the Netherlands (5.4%). Ramipril was developed by the 
German company Hoechst which became part of the 
French Sanofi group by means of acquisition.
Enalapril (developed by Merck (USA) is the most 
popular anti-hypertensive therapy in the Netherlands 
Table 3
Market data of ACE inhibitor therapies in Europe
API Clinical Rank
Sales 
VolUK
Sales 
VolDE
Sales 
VolNL
Sales 
VolFR
Sales 
VolIT
Sales 
VolES 
Sales 
VolHU
Sales 
VolRO
Sales 
VolPL
CU 
MAT/6/16 
(%) 
CU 
MAT/6/16 
(%) 
CU 
MAT/6/16 
(%) 
CU 
MAT/6/16 
(%) 
CU 
MAT/6/16 
(%) 
CU 
MAT/6/16 
(%) 
CU 
MAT/6/16 
(%) 
CU 
MAT/6/16 
(%) 
CU 
MAT/6/16 
(%) 
Innov. Country
ramipril 1 58.8 72.1 5.4 46.1 60.0 17.6 33.0 18.5 54.8 Hoechst>Sanofi DE, FR
enalap-
ril 2 5.1 15.9 30.7 5.5 15.4 66.7 17.3 28.4 12.1 Merck
USA 
(GER)
fosino- 
pril 2 0.1 0.2 5.9 1.3 1.1 0.5 1.9 3.5 -
Bristol-My-
ers Squibb USA
lisino-
pril 2 22,9 9,0 23,9 3,3 5,3 6,1 3,3 6,5 5,9
Merck > 
Astra Zeneca UK, SE
perindo-
pril 2 11.9 0.1 28.2 37.5 6.8 0.9 37.1 23.2 12.9 Servier FR
zofeni- 
pril 2 - - 0.4 0.8 8.0 - 5.4 1.6 Menarini IT
capto-
pril 3 0.6 1.9 2.8 1.4 0.6 4.5 5.7 7.3 5.2 Squibb USA
trando-
la-pril 4 0.3 0.0 - 2.4 0.1 0.1 0.3 0.5 1.2 Abbott USA
benaz-
epril 5 - 0.4 0.0 0.9 0.9 0.3 0.2 0.2 0.4 Novartis CH
quinapril 5 0.3 0.3 2.6 0.7 1.2 0.8 1.2 6.4 3.1 Pfizer USA
moexi- 
pril 5 0.0 0.0 - 0.0 0.1 - - -
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(30.7%) and Spain (66.7%) based on sales volume, and 
has a significant share in the other investigated coun-
tries too, with the exception of the United Kingdom 
and France.
Lisinopril is used for the treatment of hypertension 
in significant quantities in the United Kingdom (22.9%) 
and Netherlands (23.9%) among the investigated coun-
tries. The original developer was Merck (USA) but the 
distribution of the active pharmaceutical ingredient 
was taken by Astra Zeneca (UK, SE). Based on one 
of our previous researches it is interesting data that 
investigating the pharmaceutical market of the United 
States of America, lisinopril leads the sales list of ACE 
inhibitors with a share over 77% (IMS database, mov-
ing annual total (9/15); ratio of sales value based on 
thousand tablets sold). 
Perindopril reaches outstanding sales data in Hun-
gary (37.1%, first rank) and France (37.5%). Significant 
sales volumes are characteristic to the Dutch (28.2%) 
and Romanian (23.2%) perindopril market, and its 
share is over 10% in the UK and Polish market. Perin-
dopril was developed by the French company, Servier. 
Interestingly, captopril which is noted as the first 
ACE inhibitor therapy but lagging behind in the clini-
cal ranking, has a market share over 5% in the Hungar-
ian (5.7%), Polish (5.2%), and Romanian (7.3%) mar-
ket. (The average price level of captopril is the lowest 
among ACE inhibitors).
The sales data of the countries introduced in Table 
3 were subjected to multidimensional scaling. These 
nine European countries can therefore be compared by 
the market data of the 11 different ACE inhibitors. Sim-
ilarly to the previous analysis, the SPSS 22.0 software 
package was used. We set an ’Ideal’ variant in the data-
base symbolizing the country which can be considered 
as ideal in terms of clinical evidence with 100% rami-
pril sales. The value of the stress indicator is 0.0512 
(Kruskal’s stress formula), and R2 is 0.987 indicating 
a very appropriate statistical fit. The first dimension is 
characterized by higher dispersion. 
The following groups of countries can be distin-
guished based on the results:
•  DE, IT, UK, PL: Ramipril has the highest market 
share as the most recommended API concerning 
clinical evidence. Besides ramipril we can typi-
cally identify one (maybe two) ACE inhibitor with 
significant market performance, from the second 
group of the clinical rank list.  Germany is the 
closest to the ideal state in terms of ACE inhibitor 
consumption. 
•  FR, HU: These countries are characterized by per-
indopril and ramipril dominance. As both active 
pharmaceutical ingredients are the products of 
French pharmaceutical companies, these two coun-
tries may be described as having strong French 
influence in the field of ACE inhibitors. (Based on 
consultation with pharmaceutical experts, in Hun-
gary, this phenomenon may be explained by the 
marketing activity of EGIS acquired by Servier, the 
producer of perindopril). The example of the active 
pharmaceutical ingredient zofenipril can be men-
tioned in parallel with perindopril. The API, devel-
oped by Menarini (IT) reaches sales volume above 
5% only in Italy (8%) and Romania (5.4%). Both 
examples assume some country of origin effect in 
the market of anti-hypertensive drugs. Consequent-
ly the country of origin effect may be an important 
influencing factor in the market performance of 
other active pharmaceutical ingredients (e.g. rami-
pril, lisinopril) as well. Due to the above, this effect 
is worth to be researched further in the future.
•  RO, NL: Dominance of enalapril and perindopril. 
Interestingly, the literature emphasizes that in the 
Dutch market, doctors do not make their decisions 
based on price level in the process of drug pre-
scription. However, in the case of ACE inhibitors, 
it can be concluded that the factor influencing 
prescription in the Dutch pharmaceutical market 
is not clinical evidence. Of the investigated coun-
tries, the Romanian market of ACE inhibitors is 
the most fragmented between the various active 
ingredients. 
•  ES: The Spanish ACE inhibitor market is obvious-
ly ruled by enalapril. Besides enalapril ramipril 
reaches considerable sales. 
By evaluating the effect of the ACE inhibitors’ price 
level on their market performance, the following con-
clusions can be made. The price level of captopril, the 
 
 
 
Figure 4
Results of the multidimensional scaling 
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first noted ACE inhibitor is the lowest in the investigated 
countries. However, from the clinical point of view, cap-
topril lags behind ramipril (first rank) and other active 
pharmaceutical ingredients that are listed in the second 
place. This may explain why it also lags behind in terms 
of market performance in spite of being the cheapest an-
ti-hypertensive drug. However, in three countries (HU, 
RO, PL) captopril is still able to reach a share above 
5%. Most probably this phenomenon can be explained 
by low-income consumer groups with increased price 
sensitivity even against cheap ACE inhibitor therapies. 
This phenomenon exists even though in the European 
healthcare systems patients sense only a small fragment 
of the payable price. Another explanation is that mostly 
elderly patients whose condition is manageable with the 
captopril was initiated decades ago and the doctor does 
not want to switch for another therapy.
By examining further sales data we can conclude 
that in the investigated countries, usually those thera-
pies can reach high shares in volume which price level 
is lower than the average (the price pattern of the APIs 
differ in the involved countries).  It is important to note 
that the tools of drug policy mentioned at the begin-
ning of the literature summary also play an important 
role in the formation of the price level, so drug policy 
tools influence prescription patterns directly and indi-
rectly too. (Assuming a properly working healthcare 
system – on an economic basis – the therapy which 
has the most appropriate long-term benefit-risk ratio on 
aggregate level has to be preferred within the health-
care system.) Comparing the drug policy tools with 
the sales data, we cannot draw general conclusions. 
It means that the demand and supply side tools have 
significant impact on the generic competition on the 
aggregate level (for instance stimulating the spread of 
generic share) but has less effect in the development 
of the proportion amongst individual drug therapies in 
the same indication group. A factor that is recommend-
ed to investigate in the future is the impact of clinical 
guidelines and clinical literature on physician decisions 
(including behavioral elements, i.e. awareness towards 
and compliance with clinical guidelines and literature). 
In contrast with the above conclusions, in some cas-
es we can detect significant market share despite high-
er than average price levels. In the German market, the 
price of ramipril, which has a 72.1% market share and is 
considered to be clinically the most appropriate is high-
er than the average price level of ACE inhibitors. The 
outstanding sales data of ramipril in the German mar-
ket may have several reasons. From the clinical point of 
view, Ramipril is the preferred API in the ACE group, 
furthermore its price level is only slightly (2%) higher 
than the average price level. In German ramipril sales, 
country-effect may also play a role via visits by phar-
maceutical representatives. A more outstanding exam-
ple compared to ramipril is the high level of perindo-
pril sales, which is characteristic to several countries. 
Perindopril has reached sales between 23% and 37.5% 
in the Romanian, Hungarian, French and Dutch mar-
kets despite its significantly high price level compared 
to the average (the range between +13.8 and +49.3%). 
Zofenipril, the most exceptional example in this respect, 
has an 8% market share in the Italian market in spite of 
its 65.5% higher price, and 5.4% share beside a 164% 
higher price in the Romanian market. This anomaly is 
attributable to the persuasive function of sales represen-
tatives. Consequently the mentioned Consequently the 
mentioned country-of-origin effect could have a signif-
icant impact on decreasing price sensitivity could have 
a significant impact on decreasing price sensitivity. This 
relationship should be analyzed in detail in the future.
Summary, Outlook, Limitations of the Research
As a summary, the main goal of the recent study is to 
introduce a novel approach for the evaluation of the re-
lationship between the pharmaceutical products’ clini-
cal evidence (theoretically the main product feature for 
the patients and physicians) and their market perfor-
mance. In theory, the better efficacy and safety profile 
should end up in higher sales in volume (DOT). As-
suming that the active pharmaceutical ingredients can 
be ranked based upon their safety and clinical profile, 
the article analyzes the relationship between the clini-
cal evidence and the market performance. The article 
briefly mentions further factors that have a significant 
impact on the analyzed relationship, but deliberately 
does not involve them in the analysis. There is one ex-
ception, because the article touches the impact of the 
price level of drug therapies. 
The analysis was performed on the market of an-
ti-hypertensive drugs in 9 European markets. It can be 
stated in general when comparing ARB and ACE in-
hibitor therapies that the clinically preferred ARB ther-
apies were prescribed in the largest amount in France, 
in almost 50%. Based on the comparison of these two 
therapeutic groups, we cannot state that clinical ev-
idence is the most dominant factor in the process of 
drug prescription. As a limitation, we must mention 
that ARB and ACE therapies are equivalent in terms of 
efficacy, ARB therapies’ superiority comes from their 
slightly-better side effect profile. This minor clinical 
difference is probably overshadowed by their higher 
price level. Nevertheless, we conclude that the ARB 
market share of lower-income countries (HU, PL, RO) 
lags behind that of the higher-income countries. A fur-
ther result is that the countries involved in the study 
could be categorized by a well-defined 2×2 matrix. 
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The group of ACE inhibitors was analyzed more 
in-depths in the level of individual active pharmaceu-
tical ingredients. Of the members of a five-grade scale, 
typically the active pharmaceutical ingredients ranked 
into the first and second category as per clinical evi-
dence reach considerable sales. Analyzing the market 
performance of drugs it seems that clinical evidence 
may therefore play an important role in the decision 
making process of drug purchase. When introducing 
the results we also point out the determinative role of 
price level, emphasizing the experienced anomalies. 
Beside the role of clinical evidence and price level, our 
data show country-of-origin effect-effect in the market 
of ACE inhibitors. In several cases this also explains 
the anomalies experienced by investigating the role of 
price level. Beyond the dominant role of product char-
acteristics, the marketing activity of manufacturers has 
an obvious effect on the market performance of active 
pharmaceutical ingredients; however it was only men-
tioned in a superficial manner. 
A further limitation of our research is that it only 
involves one therapy group and was conducted in the 
prescription drug market. Therefore the available data 
do not allow us to make a general conclusion that can 
be considered valid for the whole pharmaceutical in-
dustry. For general pharmaceutical investigations, we 
set four main research directions for the future:  de-
tailed investigation of the elements of the presented de-
cision making pathway, the evaluation of the effect of 
the funding and reimbursement regulations, the effects 
of factors influencing the prescribing doctor’s deci-
sion, emphasizing the detailed evaluation of the coun-
try-of-origin effect, as well as extending the research to 
further indication groups.
Concerning the managerial implications, the in-
troduced approach and the findings of the future stud-
ies may be supportive for the better understanding of 
the purchase decision process. If the clinical ranking 
can be accepted as a general quality indicator for dif-
ferentiating between the APIs, the effect of the ad-
ditional significant factors can be compared between 
the countries more easily. This may help to design ge-
neric portfolios for pharmaceutical companies. From 
the patients’ side an easy-to-understand tool could be 
also beneficial.
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